MannKind (NASDAQ:MNKD) achieved key clinical development milestones for its investigational lung disease therapy, pushing its dry powder formulation of nintedanib further into mid-stage clinical testing.
KBR (NYSE:KBR) announced that its Mission Technology Solutions unit has been awarded a landmark $8 billion ceiling contract by the U.S. National Science Foundation (NSF) to provide comprehensive science and engineering support for the U.S. Antarctic Program.
T1 Energy (NYSE:TE) has entered into a definitive agreement to acquire KORE Power for an aggregate enterprise value of approximately $32 million, securing a specialized foothold in the rapidly expanding utility-scale energy storage sector.
IDEAYA Biosciences (NASDAQ:IDYA) has entered into a clinical collaboration agreement with Swiss healthcare giant Roche to evaluate a novel combination therapy aimed at a genetically distinct and difficult-to-treat form of pancreatic cancer.
Partners Group CEO David Layton discusses the firm's move to cap withdrawals at one of its evergreen private equity funds amid heightened redemption pressure. He speaks with Matt Miller on "Bloomberg Brief."
Apple (NASDAQ:AAPL) has agreed to supply local financial data to India's antitrust regulator, dropping its long-standing refusal to do so as part of a high-stakes probe into its mobile app marketplace dominance.
Victoria’s Secret shares jumped about 50% in a single session - the best day in the company’s history - after earnings showed sales up 15%, profit nearly quadrupled and earnings per share roughly double Wall Street expectations.
Zhihu (NYSE:ZH) reported a sharp increase in adjusted profitability for the first quarter of 2026, overcoming a contraction in top-line revenue through disciplined operational efficiency and reduced overhead.
DBV Technologies (NASDAQ:DBVT) has screened the first participant in its THRIVE study, evaluating the Viaskin Peanut patch in infants aged 6 to 12 months over a multi-year period.
Zenas BioPharma (NASDAQ:ZBIO) reported positive late-stage clinical trial results for its experimental autoimmune therapy, hitting its primary and all key secondary targets in a study that could position the treatment as a new standard of care for a rare, debilitating inflammatory condition.
Figure Technology Solutions (NASDAQ:FIGR) released preliminary operating data for May 2026 on Wednesday, demonstrating significant year-over-year acceleration across its blockchain-native capital marketplace.
Johnson & Johnson (NYSE:JNJ) disclosed new data on Wednesday showing its experimental autoimmune treatment, nipocalimab, yields stronger clinical results in patients with higher concentrations of specific disease-driving biomarkers.
_1413281_640x360_2502317123617-640x360.webp&w=3840&q=75)
